April - June 2022, Volume 18, Issue 2

Pratama KG, Tandarto K, Hengky A

Weight Loss Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients with Obesity without Diabetes: a Systematic Review

Acta Endo (Buc) 2022, 18 (2): 216-224
doi: 10.4183/aeb.2022.216

Context. Obesity is a chronic disorder with excessive accumulation and hypertrophy of adipose cells. Selective sodium-glucose cotransporter-2 (SGLT2) Inhibitor has shown an effect of weight loss in several studies. However, weight loss in patients with obesity without diabetes remains unclear. Objective. This systematic review aims to address the weight loss effects of SGLT 2 inhibitors in obese subjects without diabetes. Methods. We incorporated search engines from Pubmed, EBSCO host, and Proquest. The inclusion criteria for this research were full-text, written in English, written in Bahasa Indonesia, reported the effect of SGLT 2 inhibitors for weight loss in obese patients, the design of the studies, outcomes, and the results of the study. We created a data extraction table to gather the required data for the review. The exclusion criteria for this study were incomplete outcomes, not full-text studies, case reports, literature review, and irrelevant studies. Results. A total of 451 studies were identified from research database. There are 7 studies eligible to be included in this review. Weight loss effects of SGLT2 Inhibitors were observed in all the studies included in this review. Conclusion. SGLT2 inhibitor is an effective weight loss therapy in patients with obesity without diabetes.

Keywords: Obesity, SGLT2 Inhibitors, Weight Loss.

Correspondence: Kevin Gracia Pratama MD, Rumah Sakit Ken Saras, General Medicine, Jl. Soekarno Hatta No.km.29, Kebonan, Randugunting, Kec. Bergas, Jawa Tengah, Semarang Regency, Central Java, 50552, Indonesia, E-mail: kevingracia14@gmail.com